Gilead Sciences' (GILD) Hold Rating Reiterated at Needham & Company LLC

Gilead Sciences (NASDAQ:GILD - Get Free Report)'s stock had its "hold" rating reiterated by research analysts at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports.

Several other equities analysts have also issued reports on GILD. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Piper Sandler lifted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, March 11th. Finally, Oppenheimer lifted their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a report on Tuesday, March 4th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $109.43.

Gilead Sciences Trading Up 0.7 %

Shares of NASDAQ:GILD traded up $0.75 during trading on Friday, reaching $104.96. 3,223,742 shares of the company were exchanged, compared to its average volume of 7,497,675. The firm has a market capitalization of $130.69 billion, a PE ratio of 283.68, a P/E/G ratio of 0.71 and a beta of 0.32. The business's fifty day simple moving average is $109.07 and its 200-day simple moving average is $98.52. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company posted ($1.32) earnings per share. On average, research analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders have sold 302,785 shares of company stock valued at $30,540,875. Company insiders own 0.27% of the company's stock.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences in the first quarter valued at $25,000. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. Finally, Goodman Advisory Group LLC acquired a new stake in Gilead Sciences in the first quarter valued at approximately $29,000. Institutional investors and hedge funds own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.